Solid tissue malignancies are often detected at such an advanced stage that almost any therapy is doomed to failure. Therapy directed at early lesions should have a higher probability of success, but the early events in neoplastic progression occur sporadically and unpredictably. These early neoplastic cells are therefore difficult to investigate in humans. Designing effective strategies to eliminate cells in early stages of neoplastic progression is currently impossible because their fundamental characteristics are unknown. A large body of evidence now indicates that the generation of a malignant cell requires many genetic changes that would be improbable in a normal cell. Although it is often assumed that genomic instability develops only in association with defects in DNA repair pathways, several recent investigations have revealed multiple sources of genetic effort in the cell cycle itself. The goal of this proposal is to determine the properties of the genomically unstable and abnormally proliferating cell, which appears to be an early abnormality in the development of most, if not all, solid tissue neoplasms. The investigations will be performed in a transgenic mouse model in which cell cycle abnormalities and genomic instability develop in 100% of individuals at defined stages and in which they can be clearly related to the later formation of tumors. Only after the properties of these early neoplastic cells have been defined in such a model system can effective strategies to eliminate them be devised.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA055814-03
Application #
2096922
Study Section
Pathology B Study Section (PTHB)
Project Start
1992-02-01
Project End
1995-01-31
Budget Start
1994-02-01
Budget End
1995-01-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Low, D E; Levine, D S; Dail, D H et al. (1999) Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 94:80-5
Kristal, A R; Baker, M S; Flaherty, M J et al. (1995) A pilot study of DNA aneuploidy in colorectal adenomas and risk of adenoma recurrence. Cancer Epidemiol Biomarkers Prev 4:347-52
Ramel, S; Sanchez, C A; Schimke, M K et al. (1995) Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Pancreas 11:213-22
Cross, S M; Sanchez, C A; Morgan, C A et al. (1995) A p53-dependent mouse spindle checkpoint. Science 267:1353-6
Neshat, K; Sanchez, C A; Galipeau, P C et al. (1994) p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 106:1589-95
Blount, P L; Galipeau, P C; Sanchez, C A et al. (1994) 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 54:2292-5
Neshat, K; Sanchez, C A; Galipeau, P C et al. (1994) Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol 59:577-83
Neshat, K; Sanchez, C A; Galipeau, P C et al. (1994) Barrett's esophagus: the biology of neoplastic progression. Gastroenterol Clin Biol 18:D71-6
Meltzer, S J; Yin, J; Manin, B et al. (1994) Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 54:3379-82
Reid, B J; Sanchez, C A; Blount, P L et al. (1993) Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105:119-29

Showing the most recent 10 out of 12 publications